View in EDS

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Authors: Oza, Amit M1 amit.oza@uhn.ca, Matulonis, Ursula A2, Malander, Susanne3, Hudgens, Stacie4, Sehouli, Jalid5, del Campo, Josep M6, Berton-Rigaud, Dominique7, Banerjee, Susana8, Scambia, Giovanni9, Berek, Jonathan S10, Lund, Bente11, Tinker, Anna V12, Hilpert, Felix13, Vázquez, Isabel Palacio14, D'Hondt, Véronique15, Benigno, Benedict16, Provencher, Diane17, Buscema, Joseph18, Agarwal, Shefali19, Mirza, Mansoor R20
Source: Lancet Oncology. Aug2018, Vol. 19 Issue 8, p1117-1125. 9p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(18)30333-4